Blueprint Medicines (BPMC) Misses Q2 EPS by 7c

Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($0.86), $0.07 worse than the analyst estimate of ($0.79).

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Solstice acquiring Element Solutions in $14.5B cash and stock deal
• Buy the pullback in chip stocks, JPM's Matejka says
• Harley-Davidson (HOG) PT Raised to $30 at DA Davidson: 'Moving in The Right Direction'